Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cholangiocarcinoma | Research

Cancer-specific survival in patients with cholangiocarcinoma after radical surgery: a Novel, dynamic nomogram based on clinicopathological features and serum markers

Authors: Shurui Zhou, Yue Zhao, Yanzong Lu, Weiling Liang, Jianmin Ruan, Lijun Lin, Haoming Lin, Kaihong Huang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

This study aims to (1) identify preoperative testing-based characteristics associated with enhanced prognosis and survival for cholangiocarcinoma patients, and (2)create a distinctive nomogram to anticipate each patient’s cancer-specific survival (CSS).

Methods

Retrospective analysis was performed on 197 CCA patients who underwent radical surgery at Sun Yat-sen Memorial Hospital; they were divided into a 131-person “training cohort” and a 66-person “internal validation cohort.“ The prognostic nomogram was created following a preliminary Cox proportional hazard regression search for independent factors influencing the patients’ CSS. Its applicable domain was examined via an external validation cohort, which included 235 patients from the Sun Yat-sen University Cancer Center.

Results

The median follow-up period for the 131 patients in the training group was 49.3 months (range, 9.3 to 133.9 months). One-, three-, and five-year CSS rates were 68.7%, 24.5%, and 9.2%, respectively, with the median CSS length being 27.4 months (range: 1.4 to 125.2 months). PLT, CEA, AFP, tumor location, differentiation, lymph node metastasis, chemotherapy, and TNM stage were determined to be independent risk factors for CCA patients by univariate and multivariate Cox proportional hazard regression analysis. We were able to accurately predict postoperative CSS after incorporating all of these characteristics into a nomogram. The AJCC’s 8th edition staging method’s C-indices were statistically substantially (P < 0.001) lower than the nomogram’s C-indices (0.84, 0.77, and 0.74 in the training, internal and external validation cohorts respectively).

Conclusions

A realistic and useful model for clinical decision-making and the optimization of therapy is presented as a nomogram that includes serum markers and clinicopathologic features for predicting postoperative survival in cholangiocarcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–80.PubMedCrossRef Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–80.PubMedCrossRef
2.
go back to reference Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.PubMedCrossRef Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.PubMedCrossRef
3.
go back to reference Global Burden of Disease, Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer incidence, mortality, years of Life Lost, Years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2017: a systematic analysis for the global burden of Disease Study. JAMA Oncol. 2019;5(12):1749–68.CrossRef Global Burden of Disease, Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer incidence, mortality, years of Life Lost, Years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2017: a systematic analysis for the global burden of Disease Study. JAMA Oncol. 2019;5(12):1749–68.CrossRef
4.
go back to reference Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical treatments of hepatobiliary cancers. Hepatology. 2021;73(Suppl 1):128–36.PubMedCrossRef Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical treatments of hepatobiliary cancers. Hepatology. 2021;73(Suppl 1):128–36.PubMedCrossRef
5.
6.
go back to reference Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7.PubMedCrossRef Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7.PubMedCrossRef
8.
go back to reference Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol. 2015;67(2):204–9.PubMedCrossRef Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol. 2015;67(2):204–9.PubMedCrossRef
9.
go back to reference Chen S, Liu Y, Yang J, Liu Q, You H, Dong Y, et al. Development and validation of a Nomogram for Predicting Survival in male patients with breast Cancer. Front Oncol. 2019;9:361.PubMedPubMedCentralCrossRef Chen S, Liu Y, Yang J, Liu Q, You H, Dong Y, et al. Development and validation of a Nomogram for Predicting Survival in male patients with breast Cancer. Front Oncol. 2019;9:361.PubMedPubMedCentralCrossRef
12.
go back to reference Wang YQ, Zhu YJ, Pan JH, Xu F, Shao XG, Sha JJ, et al. Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large chinese cohort study. Asian J Androl. 2017;19(5):579–85.PubMedCrossRef Wang YQ, Zhu YJ, Pan JH, Xu F, Shao XG, Sha JJ, et al. Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large chinese cohort study. Asian J Androl. 2017;19(5):579–85.PubMedCrossRef
13.
go back to reference Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of systemic inflammation response index and platelet-to-lymphocyte ratio as a novel prognostic marker of Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. Front Oncol. 2019;9:914.PubMedPubMedCentralCrossRef Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of systemic inflammation response index and platelet-to-lymphocyte ratio as a novel prognostic marker of Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. Front Oncol. 2019;9:914.PubMedPubMedCentralCrossRef
14.
go back to reference You W, Yan L, Cai Z, Xie L, Sheng N, Wang G, et al. Clinical significances of positive postoperative serum CEA and post-preoperative CEA increment in stage II and III colorectal Cancer: a Multicenter Retrospective Study. Front Oncol. 2020;10:671.PubMedPubMedCentralCrossRef You W, Yan L, Cai Z, Xie L, Sheng N, Wang G, et al. Clinical significances of positive postoperative serum CEA and post-preoperative CEA increment in stage II and III colorectal Cancer: a Multicenter Retrospective Study. Front Oncol. 2020;10:671.PubMedPubMedCentralCrossRef
15.
go back to reference Huang C, Liu Z, Xiao L, Xia Y, Huang J, Luo H, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric Cancer with peritoneal dissemination. Front Oncol. 2019;9:1159.PubMedPubMedCentralCrossRef Huang C, Liu Z, Xiao L, Xia Y, Huang J, Luo H, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric Cancer with peritoneal dissemination. Front Oncol. 2019;9:1159.PubMedPubMedCentralCrossRef
16.
go back to reference Liu S, Wang M, Zheng C, Zhong Q, Shi Y, Han X. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. Clin Biochem. 2020;79:54–60.PubMedCrossRef Liu S, Wang M, Zheng C, Zhong Q, Shi Y, Han X. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. Clin Biochem. 2020;79:54–60.PubMedCrossRef
17.
go back to reference Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med. 2009;360(5):491–9.PubMedCrossRef Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med. 2009;360(5):491–9.PubMedCrossRef
18.
go back to reference Weiser TG, Makary MA, Haynes AB, Dziekan G, Berry WR, Gawande AA, et al. Standardised metrics for global surgical surveillance. Lancet. 2009;374(9695):1113–7.PubMedCrossRef Weiser TG, Makary MA, Haynes AB, Dziekan G, Berry WR, Gawande AA, et al. Standardised metrics for global surgical surveillance. Lancet. 2009;374(9695):1113–7.PubMedCrossRef
19.
go back to reference Dessau RB, Pipper CB. [‘’R”--project for statistical computing]. Ugeskr Laeger. 2008;170(5):328–30.PubMed Dessau RB, Pipper CB. [‘’R”--project for statistical computing]. Ugeskr Laeger. 2008;170(5):328–30.PubMed
20.
go back to reference Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.PubMedCrossRef Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.PubMedCrossRef
21.
go back to reference Chen X, Pang Z, Wang Y, Bie F, Zeng Y, Wang G, et al. The role of surgery for atypical bronchopulmonary carcinoid tumor: development and validation of a model based on Surveillance, Epidemiology, and end results (SEER) database. Lung Cancer. 2020;139:94–102.PubMedCrossRef Chen X, Pang Z, Wang Y, Bie F, Zeng Y, Wang G, et al. The role of surgery for atypical bronchopulmonary carcinoid tumor: development and validation of a model based on Surveillance, Epidemiology, and end results (SEER) database. Lung Cancer. 2020;139:94–102.PubMedCrossRef
22.
go back to reference Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.PubMedCrossRef Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.PubMedCrossRef
23.
go back to reference Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.PubMedCrossRef Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.PubMedCrossRef
26.
go back to reference Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.PubMedCrossRef Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.PubMedCrossRef
27.
go back to reference Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105(11):1408–16.PubMedCrossRef Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105(11):1408–16.PubMedCrossRef
28.
go back to reference Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.PubMedCrossRef Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.PubMedCrossRef
29.
go back to reference Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2):170–8.PubMed Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2):170–8.PubMed
30.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef
31.
go back to reference Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, et al. Quality of life in patients with Advanced Cancer: Differential Association with Performance Status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–75.PubMedPubMedCentralCrossRef Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, et al. Quality of life in patients with Advanced Cancer: Differential Association with Performance Status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–75.PubMedPubMedCentralCrossRef
32.
go back to reference Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018;33(6):965–83.PubMedPubMedCentralCrossRef Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018;33(6):965–83.PubMedPubMedCentralCrossRef
33.
go back to reference Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90.PubMedPubMedCentralCrossRef Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90.PubMedPubMedCentralCrossRef
34.
go back to reference Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, et al. Platelet count and survival in patients with colorectal cancer–a preliminary study. Thromb Haemost. 1998;79(5):916–8.PubMedCrossRef Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, et al. Platelet count and survival in patients with colorectal cancer–a preliminary study. Thromb Haemost. 1998;79(5):916–8.PubMedCrossRef
35.
go back to reference Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64(4):501–5.PubMedCrossRef Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64(4):501–5.PubMedCrossRef
36.
go back to reference Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38(7):562–7.PubMedCrossRef Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38(7):562–7.PubMedCrossRef
37.
go back to reference Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33.PubMedCrossRef Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33.PubMedCrossRef
38.
go back to reference Qiang Z, Zhang W, Jin S, Dai K, He Y, Tao L, et al. Carcinoembryonic antigen, alpha-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: a retrospective cohort study. Ann Hepatol. 2021;20:100242.PubMedCrossRef Qiang Z, Zhang W, Jin S, Dai K, He Y, Tao L, et al. Carcinoembryonic antigen, alpha-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: a retrospective cohort study. Ann Hepatol. 2021;20:100242.PubMedCrossRef
39.
go back to reference Moro A, Mehta R, Sahara K, Tsilimigras DI, Paredes AZ, Farooq A, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(8):2888–901.PubMedCrossRef Moro A, Mehta R, Sahara K, Tsilimigras DI, Paredes AZ, Farooq A, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(8):2888–901.PubMedCrossRef
40.
go back to reference Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, et al. Molecular evolution of early-onset prostate Cancer identifies molecular risk markers and clinical trajectories. Cancer Cell. 2018;34(6):996–1011e8.PubMedPubMedCentralCrossRef Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, et al. Molecular evolution of early-onset prostate Cancer identifies molecular risk markers and clinical trajectories. Cancer Cell. 2018;34(6):996–1011e8.PubMedPubMedCentralCrossRef
41.
go back to reference Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, et al. Overall survival and clinical characteristics of BRCA-Associated Cholangiocarcinoma: a Multicenter Retrospective Study. Oncologist. 2017;22(7):804–10.PubMedPubMedCentralCrossRef Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, et al. Overall survival and clinical characteristics of BRCA-Associated Cholangiocarcinoma: a Multicenter Retrospective Study. Oncologist. 2017;22(7):804–10.PubMedPubMedCentralCrossRef
42.
go back to reference Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, et al. Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. HPB (Oxford). 2017;19(5):421–8.PubMedCrossRef Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, et al. Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. HPB (Oxford). 2017;19(5):421–8.PubMedCrossRef
43.
go back to reference Le Roy B, Gelli M, Pittau G, Allard MA, Pereira B, Serji B, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105(7):839–47.PubMedCrossRef Le Roy B, Gelli M, Pittau G, Allard MA, Pereira B, Serji B, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105(7):839–47.PubMedCrossRef
Metadata
Title
Cancer-specific survival in patients with cholangiocarcinoma after radical surgery: a Novel, dynamic nomogram based on clinicopathological features and serum markers
Authors
Shurui Zhou
Yue Zhao
Yanzong Lu
Weiling Liang
Jianmin Ruan
Lijun Lin
Haoming Lin
Kaihong Huang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11040-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine